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Summary. Metastatic prostatic cancer is typically 
refractory to androgen ablation therapy due to the 
presence of androgen-independent clones in the 
neoplasia. A therapeutical approach which could 
effectively control androgen-dependent and independent 
cells is, thus, needed. Maybe the failure of certain cancer 
cells to engage in apoptosis could explain the inherent 
drug resistance of many tumors. Anyway, these cells can 
retain the ability to undergo apoptosis in response to an 
adequate stimulus. We tested whether etoposide, a topo- 
isomerase I1 inhibitor, could induce apoptosis in 
androgen-dependent (LNCaP) as well as independent 
(PC-3 and DU 145) human prostate cancer cell lines. 
Morphological examination was performed, as it is 
regarded as one of the most reliable parameters for the 
detection of apoptotic changes. Complementarily, 
biochemical and flow cytometric studies were also used. 
Characteristical changes of apoptosis were demon- 
strated in PC-3, Du 145, and LNCaP cancer cells after 
treatment with etoposide. These cells, thus, retain the 
ability to undergo apoptosis under adequate conditions, 
in a promising approach to hormone refractory prostate 
cancer therapy. 
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Introduction 
Metastatic prostatic cancer which is refractory to 
hormone therapy remains an incurable disease for which 
there is no effective therapy. Nearly all men with 
metastatic prostatic cancer treated with surgically or 
chemically-induced castration have an initial, often 
dramatical, beneficial response to such androgen 
withdrawal therapy. While this initial response is of 
substantial paliative value, essentially all treated patients 
eventually relapse into an androgen insensitive state and 
sucumb to the progression of their cancer. Several 
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studies have demonstrated that the reason for this 
universal relapse of metastatic prostate cancer to 
androgen ablation is that prostate cancer within an 
individual patient is heterogeneously composed of 
clones of both androgen-dependent and independent 
cancer cells even before hormone therapy has begun 
(Kiprianou et al., 1990; Isaacs et al., 1992; Berges et al., 
1993; Denmeade and Isaacs, 1996). While the concept of 
early combinational chemohormonal therapy for prostate 
cancer is valid, for such an approach to be thera- 
peutically effective in humans, a chemotherapeutic agent 
which can effectively control the growth of the 
preexisting androgen-independent prostatic cancer cells 
must be available. 
Observations that many types of cells undergo 
apoptotic cell death, an active process, have received 
renewed attention. An understanding that tumor cell 
population dynamics depends upon changes in the 
balance of cell loss and gain has raised the possibility of 
pharmacological intervention to increase cell loss by 
apoptosis. Many anticancer drugs initiate apoptosis and 
it is possible that the failure of certain cancer cells to 
engage in apoptosis may explain the inherent drug 
resistance of many tumors. (Oberhammer et al., 1993a; 
Schwartz et al., 1993; Schwartz and Osborne, 1993; 
Schwartzman and Cidlowski, 1993). 
Combined hormone ablation and chemotherapy have 
been attempted in clinical studies with a broad spectrum 
of cytotoxic drugs. Attention has recently focused on the 
use of oral etoposide for treatment of prostate cancer. 
(Crawford et al., 1992; Pienta and Lehr, 1993; Pienta et 
al., 1994; Scherr and Fossa, 1995; Colleoni et al., 1997). 
In the present work, we tested whether etoposide, a 
topoisomerase I1 inhibitor that acts at the level of nuclear 
matrix could induce apoptosis in androgen-dependent 
(LNCaP) and independent (PC-3 and DU 145) human 
prostatic cancer cell lines. In that case, we would be able 
to demonstrate that these human metastatic prostatic 
cancer cells still retain the ability to undergo apoptosis 
so that adequate chemotherapeutical approaches could 
improve hormone refractory prostate cancer patient 
development. Morphological changes of apoptosis as 
well as biochemical and cell cycle parameters were 
assessed. 
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